Product
Help
Pricing
About
Jobs
Log in
Get started
Keyword
Add to collection
overall response
Description:
A measure of the combined response of a system, patient, or material to treatment or applied conditions, used across medical and engineering contexts.
Related topics:
Lymphoma Diagnosis and Treatment (12%),
Multiple Myeloma Research and Treatments (10%),
Hematopoietic Stem Cell Transplantation (8%)
OpenAlex ID:
keywords/overall-response
A numerical method for computing the overall response of nonlinear composites with complex microstructure
1998
·
H. Moulinec
, P. Suquet
·
Computer Methods in Applied Mechanics and Engineering
·
1,819
PDF
Ruxolitinib for Glucocorticoid-Refractory Acute Graft-versus-Host Disease
2020
·
Robert Zeiser
, Nikolas von Bubnoff
, et al.
·
New England Journal of Medicine
·
969
PDF
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial
2017
·
Alice T Shaw
, Enriqueta Felip
, et al.
·
The Lancet Oncology
·
720
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease
2021
·
Robert Zeiser
, Nicola Polverelli
, et al.
·
New England Journal of Medicine
·
605
PDF
Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis
2020
·
Franco Locatelli
, Michael B. Jordan
, et al.
·
New England Journal of Medicine
·
565
PDF
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
2022
·
Jennifer R. Brown
, Barbara Eichhorst
, et al.
·
New England Journal of Medicine
·
556
Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review
2008
·
Roberto Stasi
, Ameet Sarpatwari
, et al.
·
Blood
·
394
Immunochemotherapy With Rituximab and Overall Survival in Patients With Indolent or Mantle Cell Lymphoma: A Systematic Review and Meta-analysis
2007
·
H. Schulz
, J. F. Bohlius
, et al.
·
JNCI Journal of the National Cancer Institute
·
385
Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial
2022
·
Ahmed Omar Kaseb
, Elshad Hasanov
, et al.
·
The Lancet. Gastroenterology & hepatology
·
311
PDF
Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis
2019
·
Mario Giuliano
, Francesco Schettini
, et al.
·
The Lancet Oncology
·
206
Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study
2018
·
Martin H Voss
, Albert Reising
, et al.
·
The Lancet Oncology
·
167
Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomised, open-label, phase 3 trial
2017
·
Andrew Davies
, Francesco Merli
, et al.
·
The Lancet Haematology
·
133
Electrochemotherapy in the treatment of metastatic malignant melanoma: a prospective cohort study by InspECT
2017
·
C. Kunte
, V. Letulé
, et al.
·
British Journal of Dermatology
·
127
PDF
A Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated Extensive-Stage Small Cell Lung Cancer
2010
·
Jingwei Jiang
, Xiaohua Liang
, et al.
·
Journal of Thoracic Oncology
·
115
Topoisomerase-IIα expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel
2004
·
Virginie Durbecq
, Marianne Paesmans
, et al.
·
Molecular Cancer Therapeutics
·
106
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial
2020
·
Bruce D Cheson
, Nancy L Bartlett
, et al.
·
The Lancet Haematology
·
104
Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial
2019
·
Guillermo Garcia-Manero
, Gail Roboz
, et al.
·
The Lancet Haematology
·
99
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
2011
·
Simone Lanini
, Aoife C Molloy
, et al.
·
BMC Medicine
·
96
PDF
Rituximab biosimilar and reference rituximab in patients with previously untreated advanced follicular lymphoma (ASSIST-FL): primary results from a confirmatory phase 3, double-blind, randomised, controlled study
2017
·
Wojciech Jurczak
, Ilídia Moreira
, et al.
·
The Lancet Haematology
·
86
Efficacy of single fraction conventional radiation therapy for painful uncomplicated bone metastases: a systematic review and meta-analysis
2017
·
Ronald Chow
, Peter Hoskin
, et al.
·
Annals of Palliative Medicine
·
86
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma
1999
·
L Assersohn
, A Norman
, et al.
·
British Journal of Cancer
·
75
PDF
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
1995
·
K K Fields
, G J Elfenbein
, et al.
·
Journal of Clinical Oncology
·
73
Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer
2009
·
E.H. Tan
, J. Rolski
, et al.
·
Annals of Oncology
·
69
PDF
Efficacy, pharmacokinetics, and safety of the biosimilar CT-P10 in comparison with rituximab in patients with previously untreated low-tumour-burden follicular lymphoma: a randomised, double-blind, parallel-group, phase 3 trial
2018
·
Michinori Ogura
, Juan Manuel Sancho
, et al.
·
The Lancet Haematology
·
66
Extended vs Bolus Infusion of Broad-Spectrum β-Lactams for Febrile Neutropenia: An Unblinded, Randomized Trial
2018
·
Ron Ram
, Yael Halavy
, et al.
·
Clinical Infectious Diseases
·
65
Show more works
View as search
Works count:
234
Citation count:
9,255
Year
Topic
Type